CompletedPhase 1/2

Study in Subjects With Small Primary Choroidal Melanoma

United States57 participantsStarted 2017-02-27

Plain-language summary

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of choroidal melanoma Exclusion Criteria: * Have known contraindications or sensitivities to the study drug

What they're measuring

Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] of Light-activated AU-011

Timeframe: Informed consent through 1-2 years

Trial details

NCT IDNCT03052127

SponsorAura Biosciences

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-01-26

Results submitted2023-12-19

View on ClinicalTrials.gov More Uveal Melanoma trials